TPCW
MRNA icon

TD Private Client Wealth’s Moderna MRNA Stock Holding History

TD Private Client Wealth’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.4K Sell
1,305
-6
-0.5% -$310 ﹤0.01% 787
2026
Q1 		$66.6K Buy
1,311
+148
+13% +$6.91K ﹤0.01% 832
2025
Q4 		$34.3K Sell
1,163
-130
-10% -$3.53K ﹤0.01% 944
2025
Q3 		$33.4K Buy
1,293
+337
+35% +$9.4K ﹤0.01% 914
2025
Q2 		$26.4K Buy
956
+743
+349% +$19.6K ﹤0.01% 947
2025
Q1 		$6.04K Buy
213
+176
+476% +$6.25K ﹤0.01% 1059
2024
Q4 		$1.54K Sell
37
-302
-89% -$14.4K ﹤0.01% 1218
2024
Q3 		$22.7K Sell
339
-220
-39% -$20.2K ﹤0.01% 954
2024
Q2 		$66.4K Buy
559
+131
+31% +$16.6K ﹤0.01% 757
2024
Q1 		$45.6K Sell
428
-218
-34% -$22K ﹤0.01% 829
2023
Q4 		$64.2K Sell
646
-293
-31% -$24.6K ﹤0.01% 777
2023
Q3 		$97K Sell
939
-5,061
-84% -$565K ﹤0.01% 657
2023
Q2 		$729K Sell
6,000
-220
-4% -$29.3K 0.03% 386
2023
Q1 		$955K Sell
6,220
-2,462
-28% -$406K 0.04% 335
2022
Q4 		$1.56M Sell
8,682
-1,979
-19% -$324K 0.07% 254
2022
Q3 		$1.26M Sell
10,661
-188
-2% -$28.5K 0.06% 269
2022
Q2 		$1.55M Buy
10,849
+10,400
+2,316% +$1.49M 0.08% 245
2022
Q1 		$77.3K Buy
449
+412
+1,114% +$69.4K ﹤0.01% 687
2021
Q4 		$9.4K Sell
37
-322
-90% -$94.1K ﹤0.01% 914
2021
Q3 		$138K Buy
359
+330
+1,138% +$122K 0.01% 582
2021
Q2 		$6.81K Hold
29
– – ﹤0.01% 934
2021
Q1 		$3.8K Sell
29
-289
-91% -$41.9K ﹤0.01% 946
2020
Q4 		$33.2K Hold
318
– – ﹤0.01% 716
2020
Q3 		$22.5K Buy
318
+175
+122% +$12.2K ﹤0.01% 719
2020
Q2 		$9.18K Buy
143
+7
+5% +$383 ﹤0.01% 806
2020
Q1 		$4.07K Buy
136
+72
+113% +$1.66K ﹤0.01% 828
2019
Q4 		$1.25K Buy
+64
New +$1.14K ﹤0.01% 940

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

TD Private Client Wealth's MRNA Position: Q2 2026 in Review

TD Private Client Wealth reduced its Moderna (MRNA) stake by 0.46% in Q2 2026, selling an estimated $310 and leaving 1,305 shares worth $91.4K. The position accounts for ﹤0.01% of the portfolio, ranked #787.

TD Private Client Wealth first reported a position in MRNA in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.56M in Q4 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • TD Private Client Wealth held 1,305 shares of Moderna worth $91.4K as of Q2 2026.
  • TD Private Client Wealth sold 6 Moderna shares in Q2 2026, an estimated $310.
  • Moderna made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #787 holding.
  • TD Private Client Wealth first reported a position in Moderna in Q4 2019 and has held it in 27 quarters since.
  • TD Private Client Wealth's Moderna position peaked at $1.56M in Q4 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.